CURE continues to be an important supporter of the Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta and Winship Cancer Institute at Emory University as well as other leading pediatric cancer research institutions across the nation. Through generosity of donors, CURE is able to provide nearly $4 million in annual support to promising research projects.
In the past 12 years, CURE Childhood Cancer has contributed more than $25 million to research aimed at finding safer and more effective treatments for cancers that affect children. For the current fiscal year, we are funding 15 specific projects, including continued support of the Aflac Cancer Center Precision Medicine Program which envisions personalized, non-toxic and curative cancer therapy for all children.
In addition to the Precision Medicine Program is funding research at centers of excellence around the country.
AFLAC Cancer & Blood Disorders, Emory University
Douglas Graham MD, PhD
Aflac Cancer Center Precision Medicine Program
Kavita Dhodapkar, MD
Precision Cellular Immunotherapy of High-risk Glioma in Children
Kelly Goldsmith, MD
Optimizing Chemoimmunotherapy with DFMO in Relapsed and Refractory Neuroblastoma
Lisa Ingerski, PhD
Health Related Quality of Life Outcomes during Molecularly Targeted Therapy for the Treatment of Refractory or Progressive Pediatric Brain Tumors
Tobey MacDonald, MD
Employing Focused Ultrasound to Aid Therapeutic Delivery to Pediatric Brain Tumors
Tobey MacDonald, MD
Phase I Trial of WP1066 in Children with Refractory and Progressive Malignant Brain Tumors with Evidence of JAK2/STAT3 Pathway Activation
Robert Schnepp, MD, PhD
BMI1 as an Oncogenic Driver and Novel Target in Alveolar Rhabdomyosarcoma
Lubing Gu, MD
Development of Dual Inhibitors of MDM2 and XIAP for Treatment of Childhood Cancers
Children’s Oncology Group & Fred Hutchinson Cancer Research Center
Soheil Meshinchi, MD, PhD
Target Pediatric AML
Children’s Cancer Therapy Development Institute
Charles Keller, MD
Prediction & Validation of a Novel Drug Combination Against Anaplastic Wilms’ tumor
Baylor College of Medicine
Alexandra Stevens, MD
A Trial of Atovaquone with Conventional Chemotherapy for Pediatric AML (ATACC AML)
Lisa L. Wang, MD
Optimizing GD2.CAR T Cell Immunotherapeutic Strategies for Relapsed Osteosarcoma and Neuroblastoma
The Children’s Hospital of Philadelphia
Frank M. Balis, MD
GD2 as a Circulating Tumor Biomarker and Clinical Trial Endpoint for Neuroblastoma
Michael Chorny, PhD
Targeted Neuroblastoma Pharmacotherapy Using Nanocarriers